Balanced splicing at the Tat-specific HIV-1 3′ss A3 is critical for HIV-1 replication

被引:35
|
作者
Erkelenz, Steffen [1 ]
Hillebrand, Frank [1 ]
Widera, Marek [1 ]
Theiss, Stephan [2 ]
Fayyaz, Anaam [3 ]
Degrandi, Daniel [4 ,5 ]
Pfeffer, Klaus [5 ]
Schaal, Heiner [1 ,4 ]
机构
[1] Univ Dusseldorf, Inst Virol, D-40225 Dusseldorf, Germany
[2] Univ Dusseldorf, Inst Clin Neurosci & Med Psychol, D-40225 Dusseldorf, Germany
[3] Michigan State Univ, Plant Biol Lab, E Lansing, MI USA
[4] Univ Dusseldorf, Inst Med Microbiol, D-40225 Dusseldorf, Germany
[5] Univ Dusseldorf, Hosp Hyg, D-40225 Dusseldorf, Germany
来源
RETROVIROLOGY | 2015年 / 12卷
关键词
HIV-1; Tat; Viral transcription; Alternative splicing; SR proteins; SRSF2; SRSF6; Splicing regulatory element; SRE; HEXplorer; IMMUNODEFICIENCY-VIRUS TYPE-1; HNRNP A/B PROTEINS; PRE-MESSENGER-RNA; INTRONIC G RUN; SR PROTEINS; GENE-EXPRESSION; NEUTRALIZING ANTIBODIES; SILENCER ELEMENT; REGULATORY ELEMENTS; EXON;
D O I
10.1186/s12977-015-0154-8
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Background: The viral regulatory protein Tat is essential for establishing a productive transcription from the 5'-LTR promoter during the early phase of viral gene expression. Formation of the Tat-encoding mRNAs requires splicing at the viral 3'ss A3, which has previously been shown to be both negatively and positively regulated by the downstream splicing regulatory elements (SREs) ESS2p and ESE2/ESS2. However, using the novel RESCUE-type computational HEXplorer algorithm, we were recently able to identify another splicing enhancer (ESE5807-5838, henceforth referred to as ESEtat) located between ESS2p and ESE2/ESS2. Here we show that ESEtat has a great impact on viral tat-mRNA splicing and that it is fundamental for regulated 3'ss A3 usage. Results: Mutational inactivation or locked nucleic acid (LNA)-directed masking of the ESEtat sequence in the context of a replication-competent virus was associated with a failure (i) to activate viral 3'ss A3 and (ii) to accumulate Tat-encoding mRNA species. Consequently, due to insufficient amounts of Tat protein efficient viral replication was drastically impaired. RNA in vitro binding assays revealed SRSF2 and SRSF6 as candidate splicing factors acting through ESEtat and ESE2 for 3'ss A3 activation. This notion was supported by coexpression experiments, in which wild-type, but not ESEtat-negative provirus responded to higher levels of SRSF2 and SRSF6 proteins with higher levels of tat-mRNA splicing. Remarkably, we could also find that SRSF6 overexpression established an antiviral state within provirus-transfected cells, efficiently blocking virus particle production. For the anti-HIV-1 activity the arginine-serine (RS)-rich domain of the splicing factor was dispensable. Conclusions: Based on our results, we propose that splicing at 3'ss A3 is dependent on binding of the enhancing SR proteins SRSF2 and SRSF6 to the ESEtat and ESE2 sequence. Mutational inactivation or interference specifically with ESEtat activity by LNA-directed masking seem to account for an early stage defect in viral gene expression, probably by cutting off the supply line of Tat that HIV needs to efficiently transcribe its genome.
引用
收藏
页数:19
相关论文
共 50 条
  • [21] Broad Recognition of Circulating HIV-1 by HIV-1-specific CTLs With Strong Ability to Suppress HIV-1 Replication
    Kuse, Nozomi
    Murakoshi, Hayato
    Akahoshi, Tomohiro
    Yu, Zhang
    Chikata, Takayuki
    Borghan, Mohamed Ali
    Gatanaga, Hiroyuki
    Sakai, Keiko
    Oka, Shinichi
    Takiguchi, Masafumi
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2018, 34 : 171 - 171
  • [22] 2′,3′-Dialdehyde of ATP, ADP, and Adenosine Inhibit HIV-1 Reverse Transcriptase and HIV-1 Replication
    Schachter, Julieta
    Chaves Valadao, Ana Luiza
    Aguiar, Renato Santana
    Barreto-de-Souza, Victor
    Rossi, Atila Duque
    Arantes, Pablo Ricardo
    Verli, Hugo
    Quintana, Paula Gabriela
    Heise, Norton
    Tanuri, Amilcar
    Bou-Habib, Dumith Chequer
    Persechini, Pedro Muanis
    CURRENT HIV RESEARCH, 2014, 12 (05) : 347 - 358
  • [23] SPECIFIC HIV-1 INHIBITORS TARGETED AT THE HIV-1 RT
    DECLERCQ, E
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1993, 6 (06): : 673 - 673
  • [24] Solution Structure of the HIV-1 Exon Splicing Silencer 3
    Levengood, Jeffrey D.
    Rollins, Carrie
    Mishler, Clay H. J.
    Johnson, Charles A.
    Miner, Grace
    Rajan, Prashant
    Znosko, Brent M.
    Tolbert, Blanton S.
    JOURNAL OF MOLECULAR BIOLOGY, 2012, 415 (04) : 680 - 698
  • [25] Preliminary NMR investigation of Tat alternative splicing regulation in HIV-1
    Cabal, S
    Guittet, É
    COMPTES RENDUS CHIMIE, 2006, 9 (3-4) : 433 - 438
  • [26] The Ins and Outs of HIV-1 Tat
    Debaisieux, Solene
    Rayne, Fabienne
    Yezid, Hocine
    Beaumelle, Bruno
    TRAFFIC, 2012, 13 (03) : 355 - 363
  • [27] Cyclophilin A and HIV-1 replication
    Luban, J
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1998, 358 (01) : R758 - R758
  • [28] REGULATION OF REPLICATION OF HIV-1
    HASELTINE, WA
    CONTROL OF HUMAN RETROVIRUS GENE EXPRESSION, 1988, : 135 - 158
  • [29] HIV-1 replication cycle
    Ferguson, MR
    Rojo, DR
    von Lindern, JJ
    O'Brien, WA
    CLINICS IN LABORATORY MEDICINE, 2002, 22 (03) : 611 - +
  • [30] Residual HIV-1 replication
    Pomerantz, RJ
    BIOMEDICINE & PHARMACOTHERAPY, 2000, 54 (01) : 13 - 15